Sign up to save your podcasts
Or
Share S13 Ep30: Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S13 Ep30: Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ
In today’s episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas.
In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.
View all episodes
By OncLive® On Air
4.3
2222 ratings
In today’s episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas.
In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.
More shows like OncLive® On Air
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
495 Listeners
Research To Practice | Oncology Videos
115 Listeners
ASCO Daily News
57 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
The ONS Podcast
197 Listeners
OncoPharm
186 Listeners
JAMA Medical News
89 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Oncology Today with Dr Neil Love
57 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners